Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

Oxytocin Market is Anticipated to Reach US$ Around US$ 165 Mn by 2030 end

Published by linker 5

Posted on February 17, 2021

Featured image for article about Research Reports

Market players are focusing on presenting anesthetic oxytocin solutions to decrease labor induced snags for C-section operations.

Industry interest in the neuropeptide hormone oxytocin has surged on the back of the profound role it has in human evolution. The peptide hormone is implicated in numerical physiological processes. The global oxytocin market is slated to record a CAGR of 8.4% over the projected period, 2020-2030. The market growth is majorly underpinned by growing prevalence of pregnancy problems amid women across numerous regions. Furthermore increasing focus on averting PPH incidences will be driving demand for oxytocin.

“Initiatives by government to promote children and women’s health are supporting global efforts to enhance maternity care all over healthcare settings, thus opening notable growth prospects for the market,” comments the FMI analyst.

Request a report sample to gain comprehensive market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-11218

Oxytocin Market – Important Highlights

MEA region will generate huge growth prospects due to unceasing efforts by government authorities to found an equitable healthcare system as well as provide improved treatment to women.
Postpartum hemorrhage (PPH) is likely to remain lucrative all over the assessment period.
Hospital pharmacies will remain key beneficiary among other distribution channel as the segment is key point of contact for availing prescribed oxytocin regulating drugs.

Oxytocin Market – Drivers

Rising emphasis on antenatal care is generating growth prospects in the global market
Increasing complications in pregnancy due to high fatality rates, has boosted demand for synthetic oxytocin production across the globe.
Rising focus on postpartum hemorrhage treatment is encouraging market expansion over the forecast period.

Oxytocin Market – Restraints

Stringent curbs and regulations to limit its usage might act as a deterrent to the growth trajectory of oxytocin market.
High cost associated with the usage can hinder the market growth.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-11218

COVID-19 Impact on Oxytocin Market

Initially, a blip was experienced by healthcare providers with regard to oxytocin treatment as the industry reoriented its priorities to care for COVID infected patients. However, governments have realized the importance of maternal care and are thus directing healthcare providers to equally accommodate their resources. Moreover, experts are also considering oxytocin as a treatment option for the coronavirus.

Competitive Landscape

The oxytocin market is extremely fragmented, due to the existence of several regional and international players who are engaged in several expansion strategies, incorporating licensing agreements, product launches, collaborations, acquisitions and partnerships. Leading market players operating in the global market include Pfizer Inc., Ferring B.V., Novartis AG, Hikma Pharmaceuticals PLC, Fresenius Kabi LLC, Teva Pharmaceuticals Ltd., Endo International Plc. (Par Sterile Products, LLC), Wockhardt Ltd., Mylan N.V., Yuhan Corporation and Sun Pharmaceutical Industries Ltd.